In this 100% online Postgraduate diploma you will have updated contents and first level didactic tools that will allow you to fully manage the Hospital Clinical Pharmacology "

According to official figures and assessments of the World Health Organization, many deaths in the hospital environment are linked to inadequate selection of therapies and drugs offered to patients. This problem is closely linked to the fact that many pharmacy professionals are not up to date with the main innovations in this field and are not familiar with the most advanced products and intervention protocols available to them. This prevents them from fully assisting medical personnel in the care of gastrointestinal, cardiac or respiratory pathologies. 

TECH, based on this incidence, has designed a rigorous program that will allow students to analyze different drugs of last generation that are used today for the approach of unstable angina, heart failure or the management of tachycardia. Also, the main brocodilators used to treat Obstructive Pulmonary Disease or the antibiotics and antivirals that have revolutionized the management of respiratory infections such as COVID-19 will be discussed. 

On the other hand, the agenda covers the most efficient prokinetics and antiemetics to carry out nutritional therapeutic interventions, among other pharmacological management related to the Gastrointestinal System. Finally, this program emphasizes on the development, progression and complications resulting from Oncohematological Diseases and which are the most advanced drugs that allow to offer a better quality of life to people suffering from them. 

All the contents of this program are integrated in a 100% online platform and are complemented with high quality multimedia resources, such as videos, infographics or interactive summaries. In addition, the Relearning methodology, exclusive to TECH, will enable each student to strengthen their practical skills in a more expeditious and flexible way. At the same time, each participant will have the opportunity to adapt this update to the schedules of their convenience since the study times are not hermetic and do not require unnecessary travel to an on-site academic center. 

Acquire a high level of specialization through a personalized academic model, which allows you to organize your studies according to your schedule and individual needs"

This Postgraduate diploma in Hospital Clinical Pharmacology  contains the most complete and up-to-date scientific program on the market. The most important features include:

• The development of practical cases presented by experts in Pharmacy, Hospital Management, among others
• Graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where self-assessment can be used to improve learning
• Its special emphasis on innovative methodologies 
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments 
• Content that is accessible from any fixed or portable device with an Internet connection 

Throughout this academic itinerary you will be able to address prokinetics and antiemetics implemented in Hospital Clinical Pharmacology to develop efficient nutritional therapies"

The program’s teaching staff includes professionals from sector who contribute their work experience to this educational program, as well as renowned specialists from leading societies and prestigious universities. 

Its multimedia content, developed with the latest educational technology, will provide the professionals with situated and contextual learning, i.e., a simulated environment that will provide an immersive education programmed to learn in real situations. 

The design of this program focuses on Problem-Based Learning, by means of which the professionals must try to solve the different professional practice situations that are presented throughout the academic course. For this purpose, the students will be assisted by an innovative interactive video system created by renowned experts.  

In this program you will analyze the most advanced antihypertensive and antiarrhythmic drugs to treat conditions such as deep vein thrombosis"

Through this university program you will delve into the latest generation drugs that facilitate the care of oncohematologic emergencies and allow solving their various complications"

In 4 academic modules, this TECH Postgraduate diploma covers different areas of Hospital Clinical Pharmacology . Firstly, it delves into the most cutting-edge drugs and therapies, such as the latest generation of antihypertensives for the management of cardiovascular pathologies. In turn, it delves into the most efficient drugs for the management of respiratory problems such as asthmatic exacerbation and COPD, as well as different gastrointestinal pathologies. Lastly, the students will deal with the most efficient pharmaceutical products and methods to cover oncohematological emergencies such as Tumor Lysis Syndrome. In addition, the study of all these contents will take place 100% online, from the best platform, and with the guidance of a prestigious teaching staff. 

Use the Relearning methodology to master the practical skills offered by this TECH program in the fastest and most flexible way"

Module 1. Pharmacology of the Cardiovascular System 

1.1. Acute Coronary Syndrome (ACS) 

1.1.1. ST NSTEACS Segment-Elevation ACS 
1.1.2. Non NSTEACS ST-Segment-Elevation in ACS 
1.1.3. Unstable Angina 

1.2. Heart Failure 

1.2.1. Acute exacerbation of HF 
1.2.2. Moderate acute HF with water overload 
1.2.3. Acute hypertensive HF: acute pulmonary edema (PEA) 
1.2.4. Acute hypotensive HF: Cardiogenic Shock 
1.2.5. HF with increased systolic volume 
1.2.6. Acute HF and atrial fibrillation 
1.2.7. Acute HF and renal injury 
1.2.8. Hyperkalemia in acute HF 
1.2.9. HF of any type 

1.3. Cardiac Arrhythmias 

1.3.1. Initial management of the patient with tachycardia 
1.3.2. Unstable tachycardia with a pulse 
1.3.3. Stable tachycardia 
1.3.4. Cardio-respiratory arrest (CRA) 

1.4. Antihypertensives 

1.4.1. Angiotensin-converting enzyme inhibitors (ACEI) 
1.4.2. Angiotensin receptor blockers (ARBs)
1.4.3. Diuretics 
1.4.4. Beta-blockers 

1.5. Antiarrhythmics 

1.5.1. Class I 
1.5.2. Class II 
1.5.3. Class III 
1.5.4. Class IV 

1.6. Drugs for the treatment of coronary heart disease 

1.6.1. Platelet Aggregation Inhibitors 
1.6.2. Beta-Blockers 
1.6.3. Nitrates 
1.6.4. Angiotensin-converting enzyme inhibitors (ACEI) 

1.7. Anticoagulants 

1.7.1. Oral anticoagulants 
1.7.2. Vitamin K Antagonists 
1.7.3. Direct thrombin inhibitors 
1.7.4. Parenteral anticoagulants 

1.8. Drugs in the treatment of deep vein thrombosis and pulmonary embolism 

1.8.1. Pathophysiology of deep vein thrombosis 
1.8.2. Pharmacology of anticoagulants used in the treatment of DVT and PE 
1.8.3. Thrombolytic drugs 
1.8.4. Anticoagulant therapy in the acute and chronic management of DVT and PE 

1.9. Drugs in the Treatment of Angina Pectoris 

1.9.1. Pathophysiology of angina pectoris 
1.9.2. Fundamentals on Cardiovascular Pharmacology 
1.9.3. Classification of drugs for the treatment of Angina Pectoris
1.9.4. Use of beta-blockers in the management of Angina Pectoris: Indications and Mechanisms of Action 

1.10. Drugs in the Treatment of Pulmonary Hypertension 

1.10.1. Pathophysiology of Pulmonary Hypertension 
1.10.2. Fundamentals on Cardiovascular Pharmacology 
1.10.3. Pharmacology of PDE5 inhibitors in the treatment of Pulmonary Hypertension
1.10.4. Pharmacology of soluble guanylate cyclase stimulators in the treatment of pulmonary hypertension 

Module 2. Pharmacology of the Respiratory System 

2.1. Asthmatic exacerbation 

2.1.1. Underlying mechanisms 
2.1.2. Emerging therapies 
2.1.3. Risk Factors 
2.1.4. Prevention strategies 

2.2. Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD) 

2.2.1. Antibiotics 
2.2.2. Medical treatment 
2.2.3. Oxygen Therapy 
2.2.4. Prevention strategies 

2.3. Allergic Reaction 

2.3.1. Classification of allergies 
2.3.2. Types of allergy 
2.3.3. Diagnosis 
2.3.4. Immunotherapy 

2.4. Anaphylaxis

2.4.1. Clinical diagnosis 
2.4.2. Emergency Treatment 
2.4.3. Idiopathic Anaphylaxis 
2.4.4. Anaphylaxis in pediatrics 

2.5. Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) 

2.5.1. Risk factors and triggers for SJS and TEN 
2.5.2. Clinical and differential diagnosis of JSS and TEN 
2.5.3. Emergency management and treatment of JSS and NETs 
2.5.4. Role of drugs and infectious agents in the development of JSS and NET 

2.6. Rapid Induction and Intubation Sequence (SIIR) 

2.6.1. Indications and contraindications for SIIR 
2.6.2. Complications and risks associated with SIIR and its management 
2.6.3. Techniques and approaches for rapid and safe intubation in emergency situations
2.6.4. Monitoring and evaluation during SIIR 

2.7. Post-intubation sedoanalgesia 

2.7.1. Pharmacology of sedative and analgesic agents 
2.7.2. Assessment and monitoring of the level of sedation 
2.7.3. Strategies for pain control in postintubation patients 
2.7.4. Differences in sedation and analgesia according to the type of unit 

2.8. Pharmacology of Bronchodilators 

2.8.1. Action Mechanisms of Bronchodilators 
2.8.2. Classification of bronchodilators according to their duration of action and potency
2.8.3. Short-acting versus long-acting bronchodilators
2.8.4. Adverse effects and safety of bronchodilators 

2.9. Pharmacology of Mucolytics and Expectorants in Respiratory Diseases

2.9.1. Principles of absorption, distribution, metabolism and excretion of respiratory drugs 
2.9.2. Influence of age, gender and pathological conditions
2.9.3. Evaluation of the bioavailability of respiratory drugs 
2.9.4. Optimization of respiratory drug formulations for better absorption and bioavailability 

2.10. Pharmacology of antibiotics and antivirals in respiratory infections

2.10.1. Classification of antibiotics and antivirals used in respiratory infections
2.10.2. Mechanisms of Action of Antibiotic and Antivirals 
2.10.3. Resistance to Antibiotics and Antiviral 
2.10.4. Rational Use of Antibiotics and Antiviral 

Module 3. Pharmacology of the Gastrointestinal System 

3.1. Chronic Hepatic Disease 

3.1.1. Diagnosis and classification of chronic liver diseases
3.1.2. Biomarkers and liver function tests in diagnosis and follow-up
3.1.3. Strategies for management and prevention of disease progression
3.1.4. Pharmacological treatment of chronic liver disease

3.2. Upper gastrointestinal bleeding (UGH) 

3.2.1. Epidemiology and risk factors associated to Upper Gastrointestinal Bleeding
3.2.2. Classification and Etiology of Upper Gastrointestinal Bleeding 
3.2.3. Diagnosis and early detection methods of HDA 
3.2.4. Pharmacological Treatment of HDA 

3.3. Spontaneous Bacterial Peritonitis (SBP) 

3.3.1. Anatomy and physiology of the peritoneum and its relationship with PBE
3.3.2. Clinical diagnosis and methods of detection of spontaneous bacterial peritonitis
3.3.3. Evaluation and classification of patients with SBP 
3.3.4. Pharmacological treatment of spontaneous bacterial peritonitis 

3.4. Hydroelectrolytic Alterations 

3.4.1. Sodium 
3.4.2. Chlorine 
3.4.3. Potassium 
3.4.4. Phosphorus 

3.5. Clostridium difficile infection (CDI) 

3.5.1. Epidemiology and risk factors associated to CDI
3.5.2. CDI Diagnosis 
3.5.3. Clinical evaluation of the patient with Clostridium difficile infection
3.5.4. Pharmacological Treatment of CDI 

3.6. Complicated intra-abdominal infection (CAIbc) 

3.6.1. Epidemiology and risk factors associated to complicated intra-abdominal infection
3.6.2. Etiology and pathogenesis of cCBI 
3.6.3. Clinical evaluation of the patient with cBAI 
3.6.4. Pharmacological treatment of complicated intra-abdominal infection 

3.7. Pancreatitis 

3.7.1. Epidemiology and risk factors associated to Pancreatitis
3.7.2. Etiology and Classification of Pancreatitis 
3.7.3. Clinical diagnosis and methods of detection of Pancreatitis
3.7.4. Pharmacological treatment of acute and chronic pancreatitis

3.8. Irritable Bowel Syndrome 

3.8.1. Anatomy and physiology of the gastrointestinal system related to irritable bowel syndrome
3.8.2. Etiology and pathogenesis of irritable bowel syndrome
3.8.3. Classification and subtypes of IBS 
3.8.4. Medical treatment of irritable bowel syndrome 

3.9. Prokinetics and antiemetics 

3.9.1. Anatomy and physiology of the gastrointestinal system and the control of motility
3.9.2. Classification and mechanisms of action of prokinetics and antiemetics 
3.9.3. Indications and contraindications for the use of prokinetics and antiemetics
3.9.4. Pharmacological treatment of nausea and vomiting induced by opioids and other drugs

3.10. Pharmacology of drugs used in nutritional therapy 

3.10.1. Classification and Types of nutritional therapy 
3.10.2. Administration of drugs and enteral nutrition: interactions and special considerations 
3.10.3. Medications used for the management of malnutrition and nutritional support in critically ill patients 
3.10.4. Antibiotics and antifungals in enteral and parenteral nutrition patients 

Module 4. Pharmacology of Oncohematologic Emergencies 

4.1. Venous thromboembolism in oncohematological patients

4.1.1. Epidemiology and risk factors of VTE in oncohematologic patients 
4.1.2. Diagnosis and classification of venous thromboembolism in patients with hematologic cancers 
4.1.3. Pharmacology of anticoagulants used in the treatment and prevention of VTE in oncohematological patients
4.1.4. Use of thrombolytics in severe cases of VTE in oncohematologic patients

4.2. Tumor Lysis Syndrome 

4.2.1. Classification and diagnosis of Tumor Lysis Syndrome
4.2.2. Use of allopurinol and rasburicase in the prevention and management of hyperuricemia in SLT
4.2.3. Treatment of electrolyte disturbances in the Tumor Lysis Syndrome
4.2.4. Pharmacologic management of hyperkalemia in patients with SLT 

4.3. Tumor hypercalcemia 

4.3.1. Mechanisms of action of tumors to provoke hypercalcemia
4.3.2. Types of tumors associated with Hypercalcemia 
4.3.3. Diagnosis and classification of tumor hypercalcemia 
4.3.4. Risk assessment and prognostic factors in patients with tumor hypercalcemia 

4.4. Febrile Neutropenia 

4.4.1. Mechanisms of action of tumors to provoke hypercalcemia
4.4.2. Types of tumors associated with Hypercalcemia 
4.4.3. Diagnosis and classification of tumor hypercalcemia 
4.4.4. Risk assessment and prognostic factors in patients with tumor hypercalcemia 

4.5. Sickle cell disease 

4.5.1. Genetics and inheritance of sickle cell disease
4.5.2. Diagnosis and Classification of sickle cell disease
4.5.3. Pharmacology of drugs used in the treatment and management of SCD 
4.5.4. Use of hydroxyurea in the treatment and prevention of vasoocclusive crises 

4.6. Mechanisms of development and progression of oncohematological diseases 

4.6.1. Genetics and molecular biology of normal and cancerous hematopoietic cells 
4.6.2. Mechanisms of malignant transformation of hematopoietic cells 
4.6.3. Role of genetic mutations in hematologic oncogenesis
4.6.4. Tumor microenvironment and its influence on the progression of oncohematological diseases

4.7. Pharmacology of drugs used in for Oncohematological Emergencies 

4.7.1. Pharmacology of drugs used in stabilization and life support in oncohematological patients
4.7.2. Pharmacological management of acute hematological complications, such as severe anemia and thrombocytopenia
4.7.3. Pharmacotherapy in cases of febrile neutropenia in patients with blood cancers 
4.7.4. Use of drugs for the control of acute pain in oncohematological patients 

4.8. Treatment of febrile neutropenia 

4.8.1. Etiology and risk factors of febrile neutropenia in oncologic and hematologic patients 
4.8.2. Diagnosis and classification of Febrile Neutropenia 
4.8.3. Pharmacology of antibiotics used in the empirical treatment of febrile neutropenia
4.8.4. Use of colony-stimulating factors (G-CSF) in the management of febrile neutropenia

4.9. Treatment of tumor lysis syndrome 

4.9.1. Risk factors and prediction of the risk of developing tumor lysis syndrome 
4.9.2. Diagnosis and classification of Tumor Lysis Syndrome 
4.9.3. Pharmacology of drugs used in the prophylaxis and treatment of Tumor Lysis Syndrome 
4.9.4. Use of allopurinol and rasburicase in the prevention and management of hyperuricemia in SLT

4.10. Leukemia and Lymphoma Emergencies 

4.10.1. Oncohematologic Emergencies 
4.10.2. Acute Leukemia Emergencies 
4.10.3. Pharmacology of induction and consolidation treatments in acute leukemias 
4.10.4. Treatment of infectious complications in patients with leukemias and lymphomas 

With this 100% online Postgraduate Certificate, you will be able to acquire competencies in Hospital Clinical Pharmacology with the greatest comfort, without unnecessary trips to any on-site study center"